EUVIMEDEUVIMED entdecken
Open Access

Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa

Christophe Le Terrier iD, Patrice Nordmann iD, Charlotte Freret, Marion Seigneur, Laurent Poirel iD

Antimicrobial Agents and Chemotherapy · 18.07.2023 · 67 (7)

DOI: 10.1128/aac.00339-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.07.2023. Verfasst von Christophe Le Terrier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerla…. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, beta-Lactams. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Fribourg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of broad-spectrum β-lactamases on the susceptibility to novel β-lactamase/β-lactamase inhibitor combinations was evaluated both in Pseudomonas aeruginosa and Escherichia coli using isogenic backgrounds. Cefepime-zidebactam displayed low MICs, mainly due to the significant intrinsic antibacterial activity of zidebactam.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase Inhibitorsbeta-LactamsCefepimeMeropenemAztreonamImipenemPseudomonas aeruginosaEscherichia colibeta-LactamasesAnti-Bacterial AgentsAzabicyclo CompoundsMicrobial Sensitivity Tests

Stichwörter der Autor:innen

avibactamenmetazobactamnacubactamrelebactamsusceptibility testingtaniborbactamvaborbactamzidebactamβ-lactamase

Substanzen

Cefepimebeta-Lactamase InhibitorsMeropenembeta-LactamsAztreonamImipenembeta-LactamasesAnti-Bacterial AgentsAzabicyclo Compounds

Autor:innen und Institutionen

  • Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • Division of Intensive care unit, University hospitals of Geneva, Geneva, Switzerland.
  • Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
  • University of Lausanne and University hospital Center, Lausanne, Switzerland.

ORCID-Profile: Christophe Le Terrier, Patrice Nordmann, Laurent Poirel

Förderung

  • University of Fribourg

Zitieren

APA

Le Terrier, C., Nordmann, P., Freret, C., Seigneur, M., & Poirel, L. (2023). Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 67(7). https://doi.org/10.1128/aac.00339-23

Vancouver

Le Terrier C, Nordmann P, Freret C, Seigneur M, Poirel L. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2023;67(7). doi:10.1128/aac.00339-23

BibTeX
@article{LeTerrier2023,
  author = {Le Terrier, Christophe and Nordmann, Patrice and Freret, Charlotte and Seigneur, Marion and Poirel, Laurent},
  title = {Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {7},
  doi = {10.1128/aac.00339-23}
}
Kostenlos starten →